NIKKEI 225
38,358.30 -47.36 (-0.12%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.11 -0.82 (-1.00%) GOLD FUTURES
2,294.20 -8.70 (-0.38%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,307.96 -2,692.97 (-5.28%)
Novartis AG (0K9E.L)
| Previous close | 97.16 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 11,464 |
| Market cap | 2.206B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 0.09 |
| EPS (TTM) | 10.73 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ReutersMorphosys says takeover by Novartis on course after report of drug safety concern
BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday. Morphosys' statement came after a report by specialist website STAT News, citing two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
